Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 9 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
UNIVERSITÄT BASEL has 10 pending office actions in Biotechnology & Pharmaceuticals. These matters span 10 distinct examiners and 9 art units, showing broad examiner coverage across a slightly smaller set of technical examination units. The difference indicates that at least one art unit handles more than one matter, although the data does not identify which one.
SAHAND, SANA is the busiest examiner, with 1 pending matter. No examiner has more than one pending action in the profile. A practitioner should organize the docket by art unit and technology while preserving separate examiner-specific response strategies.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 1 (11%) |
| §112 only | 1 (11%) |
| Multi-statute (no §101) | 6 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAHAND, SANA | 1 | 63.5% | +24.0% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| CARREON, ADRIAN JOHN | 1 | 80.0% | +33.3% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
| PRAGANI, RAJAN | 1 | 52.4% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 110d overdue |
| 18280329 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | ALAM, DANYAL HASSAN | 63d |
| 19120100 | MEDICAL ENDODEVICE | SAHAND, SANA | — |
| 18840197 | SALICYLIC ACID COMPOSITIONS AND USES THEREOF | HEASLEY, MEGHAN CHRISTINE | — |
| 18548738 | DEVICE FOR MODELLING A BLOOD LABYRINTH BARRIER | CARREON, ADRIAN JOHN | — |
| 18546795 | VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER | ZARA, JANE J | — |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 110d overdue |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | PRAGANI, RAJAN | 104d overdue |
| 19120100 | MEDICAL ENDODEVICE | SAHAND, SANA | — |
| 18840197 | SALICYLIC ACID COMPOSITIONS AND USES THEREOF | HEASLEY, MEGHAN CHRISTINE | — |
| 18548738 | DEVICE FOR MODELLING A BLOOD LABYRINTH BARRIER | CARREON, ADRIAN JOHN | — |
| 18546795 | VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER | ZARA, JANE J | — |
| 18353119 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY | SKELDING, ZACHARY S | — |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 3796 | 1 |
| 1626 | 1 |
| 1672 | 1 |
| 1799 | 1 |
| 1637 | 1 |
| 1644 | 1 |
| 1641 | 1 |
| 1671 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19120100 | MEDICAL ENDODEVICE | SAHAND, SANA | 3796 | §101§103§112 | Non-Final OA | — | Pending | Apr 10, 2025 |
| 18840197 | SALICYLIC ACID COMPOSITIONS AND USES THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §103§112 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18280329 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | ALAM, DANYAL HASSAN | 1672 | §103§112 | Non-Final OA | 63d | Pending | Sep 05, 2023 |
| 18548738 | DEVICE FOR MODELLING A BLOOD LABYRINTH BARRIER | CARREON, ADRIAN JOHN | 1799 | §103§112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18546795 | VIRAL DELIVERY OF A SIALIDASE TO TREAT CANCER | ZARA, JANE J | 1637 | §103§112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18353119 | MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPY | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | — | Pending | Jul 17, 2023 |
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | HOPKINS, SAMANTHA LAKE | 1641 | §102§112Other | Final Rejection | 110d overdue | Pending | Feb 14, 2023 |
| 17772996 | ARENAVIRUSES AS VECTORS | SIFFORD, JEFFREY MARK | 1671 | §103§112Other | Final Rejection | — | Pending | Apr 28, 2022 |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | PRAGANI, RAJAN | 1614 | §103 | Final Rejection | 104d overdue | Pending | Jan 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITÄT BASEL has 9 pending office actions as of October 2026, spread across 9 art units and 9 examiners.
Sana Sahand has the most, with 1 of UNIVERSITÄT BASEL's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
